DE10305212A1 - Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom - Google Patents

Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom Download PDF

Info

Publication number
DE10305212A1
DE10305212A1 DE10305212A DE10305212A DE10305212A1 DE 10305212 A1 DE10305212 A1 DE 10305212A1 DE 10305212 A DE10305212 A DE 10305212A DE 10305212 A DE10305212 A DE 10305212A DE 10305212 A1 DE10305212 A1 DE 10305212A1
Authority
DE
Germany
Prior art keywords
hsgk1
hsgk3
gene
glaucoma
acc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10305212A
Other languages
German (de)
English (en)
Inventor
Florian Prof. Dr.med. Lang
Andreas Busjahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE10305212A priority Critical patent/DE10305212A1/de
Priority to AU2004210416A priority patent/AU2004210416A1/en
Priority to CNA2004800070348A priority patent/CN1771039A/zh
Priority to BR0407300-2A priority patent/BRPI0407300A/pt
Priority to MXPA05008394A priority patent/MXPA05008394A/es
Priority to JP2006501737A priority patent/JP2006519189A/ja
Priority to PCT/EP2004/001048 priority patent/WO2004069258A2/de
Priority to PL378399A priority patent/PL378399A1/pl
Priority to EP04708350A priority patent/EP1663246A2/de
Priority to KR1020057014582A priority patent/KR20050114214A/ko
Priority to CA002514703A priority patent/CA2514703A1/en
Priority to RU2005127808/15A priority patent/RU2005127808A/ru
Publication of DE10305212A1 publication Critical patent/DE10305212A1/de
Priority to ZA200506280A priority patent/ZA200506280B/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/166—Cataract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE10305212A 2003-02-07 2003-02-07 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom Withdrawn DE10305212A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (de) 2003-02-07 2003-02-07 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
PL378399A PL378399A1 (pl) 2003-02-07 2004-02-05 Zastosowanie genów z rodziny sgk do diagnozowania i terapii zaćmy i jaskry
EP04708350A EP1663246A2 (de) 2003-02-07 2004-02-05 Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom
BR0407300-2A BRPI0407300A (pt) 2003-02-07 2004-02-05 Usos de um inibidor funcional da proteìna hsgk1 ou da proteìna hsgk3 ou de um regulador negativo da transcrição do gene hsgk1 ou do gene hsgk3, de um ácido nucleico de filamento único ou filamento duplo e de um anticorpo, fármaco, kit para diagnóstico, e, método de triagem para identificar e caracterizar substâncias terapeuticamente ativas
MXPA05008394A MXPA05008394A (es) 2003-02-07 2004-02-05 Uso de la familia de genes sgk para el diagnostico y terapia de cataratas y glaucoma.
JP2006501737A JP2006519189A (ja) 2003-02-07 2004-02-05 白内障および緑内障を診断および治療するための、sgk遺伝子ファミリーの使用
PCT/EP2004/001048 WO2004069258A2 (de) 2003-02-07 2004-02-05 Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom
AU2004210416A AU2004210416A1 (en) 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma
CNA2004800070348A CN1771039A (zh) 2003-02-07 2004-02-05 sgk基因家族用于诊断和治疗白内障和青光眼的用途
KR1020057014582A KR20050114214A (ko) 2003-02-07 2004-02-05 백내장 및 녹내장을 진단 및 치료하기 위한 sgk 유전자패밀리의 용도
CA002514703A CA2514703A1 (en) 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma
RU2005127808/15A RU2005127808A (ru) 2003-02-07 2004-02-05 Применение генов семейства sgk для диагностики и терапии катаракты и глаукомы
ZA200506280A ZA200506280B (en) 2003-02-07 2005-08-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (de) 2003-02-07 2003-02-07 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom

Publications (1)

Publication Number Publication Date
DE10305212A1 true DE10305212A1 (de) 2004-08-19

Family

ID=32730900

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10305212A Withdrawn DE10305212A1 (de) 2003-02-07 2003-02-07 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom

Country Status (13)

Country Link
EP (1) EP1663246A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006519189A (cg-RX-API-DMAC7.html)
KR (1) KR20050114214A (cg-RX-API-DMAC7.html)
CN (1) CN1771039A (cg-RX-API-DMAC7.html)
AU (1) AU2004210416A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407300A (cg-RX-API-DMAC7.html)
CA (1) CA2514703A1 (cg-RX-API-DMAC7.html)
DE (1) DE10305212A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05008394A (cg-RX-API-DMAC7.html)
PL (1) PL378399A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005127808A (cg-RX-API-DMAC7.html)
WO (1) WO2004069258A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200506280B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191326A1 (en) * 2004-03-11 2007-08-16 Florian Lang Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
US20070203085A1 (en) * 2004-03-11 2007-08-30 Florian Lang Methods For Interfering With Fibrosis
DE102004059781A1 (de) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
WO2007037560A1 (ja) * 2005-09-30 2007-04-05 Link Genomics, Inc. Sgk2遺伝子の治療的又は診断的用途
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
EP2667885B1 (en) * 2011-01-25 2018-08-08 Monell Chemical Senses Center Compositions and methods for providing or modulating sweet taste and methods of screening therefor
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트
CN119303113A (zh) * 2024-09-03 2025-01-14 河北大学附属医院 Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535673D1 (de) * 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
CA2222562A1 (en) * 1995-06-07 1996-12-19 Jeffrey N. Miner Method for screening for receptor agonists and antagonists
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE19708173A1 (de) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Zellvolumenregulierte humane Kinase h-sgk
AU3991499A (en) * 1998-05-15 1999-12-06 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
WO2000035946A1 (en) * 1998-12-14 2000-06-22 The University Of Dundee Methods
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
AU5840300A (en) * 1999-07-14 2001-01-30 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US6416759B1 (en) * 1999-09-30 2002-07-09 The Regents Of The University Of California Antiproliferative Sgk reagents and methods
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen

Also Published As

Publication number Publication date
CA2514703A1 (en) 2004-08-19
ZA200506280B (en) 2006-05-31
WO2004069258A3 (de) 2005-02-24
KR20050114214A (ko) 2005-12-05
RU2005127808A (ru) 2006-05-27
PL378399A1 (pl) 2006-04-03
WO2004069258A2 (de) 2004-08-19
AU2004210416A1 (en) 2004-08-19
CN1771039A (zh) 2006-05-10
MXPA05008394A (es) 2005-10-05
BRPI0407300A (pt) 2006-02-07
EP1663246A2 (de) 2006-06-07
JP2006519189A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
De Kloet et al. Corticosteroids and the brain
DE60217152T2 (de) Knochen-morphogene proteine (bmp), bmp-rezeptoren und bmp-bindungsproteine und ihre verwendung bei der diagnose und behandlung des glaukoms
Melcangi et al. Age-induced decrease of glycoprotein Po and myelin basic protein gene expression in the rat sciatic nerve. Repair by steroid derivatives
DE69535214T2 (de) Verfahren zur diagnose des glaukoms
Ramirez et al. Inhibition of glycogen synthase kinase 3β (GSK3β) decreases inflammatory responses in brain endothelial cells
DE19917990A1 (de) Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
EP1663246A2 (de) Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom
Yu et al. Activation of NPFF2 receptor stimulates neurite outgrowth in Neuro 2A cells through activation of ERK signaling pathway
EP1523571B1 (de) Sgk und nedd als diagnostische und therapeutische targets
EP1313476B1 (de) SGK3 ALS DIAGNOSTISCHEs UND THERAPEUTISCHEs TARGET
DE102015208083B3 (de) Verfahren zur Prognose und/oder Diagnose einer Krankheit auf Basis von einer Probe aus Fettgewebe und Kit für dieses Verfahren
Etheredge et al. Functional compensation by other voltage-gated Ca2+ channels in mouse basal forebrain neurons with CaV2. 1 mutations
EP1594983A2 (de) Verwendung eines neuen polymorphismus im hsgk1-gen zur diagnose der hypertonie und verwendung der sgk-genfamilie zur diagnose und therapie des long-q/t-syndroms
Tao et al. Expression of urocortin 2 and its inhibitory effects on intracellular ca2+ via L-type voltage-gated calcium channels in rat pheochromocytoma (PC12) cells
DE69916672T2 (de) Androsteron-Derivate, deren Verwendung zur Unterdrückung der Bindung des Aktivatorproteins AP-1 an die DNA wie der Vermehrung der glatten Muskelzellen der Atemwege
WO2004005540A2 (de) Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen
DE60214673T2 (de) Verfahren zum screening von verbindungen auf aktivität bei der behandlung einer mit osteoklasten zusammenhängenden knochenerkrankung
DE10252806A1 (de) Verwendung von Fischlarven als Screening-Modell
DE102004059781A1 (de) Verwendung der Serum-/Glucocorticoid regulierten Kinase
DE69813677T2 (de) Humäne Serumglucocorticoidregulierte Kinase, ein Ziel für chronischer Nierenerkrankung und diabetische Nephropathie
AT502722B1 (de) Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren
EP1877803A2 (de) Verfahren zur charakterisierung der transaktivierungs- und transrespressionsaktivität von glukokortikoidrezeptor-liganden in primären immunzellen
DE10234901A1 (de) Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
DE19856301C1 (de) Regulatorisches Protein pKe#83 aus humanen Keratinozyten
DE19811326C1 (de) Verfahren zur Herstellung von Mitteln zur Behandlung von Tumorerkrankungen und zur Immunsuppression

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee